+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Anthrax Therapeutics - Global Strategic Business Report

  • PDF Icon

    Report

  • 250 Pages
  • November 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5987662
The global market for Anthrax Therapeutics is estimated at US$421.2 Million in 2023 and is projected to reach US$671.6 Million by 2030, growing at a CAGR of 6.9% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

The growth in the anthrax therapeutics market is driven by several factors, including heightened awareness of bioterrorism threats, increased government funding for biodefense initiatives, and advancements in medical technology. The ongoing investment in research and development by pharmaceutical companies is spurring the introduction of innovative treatments and vaccines. Additionally, regulatory support and the fast-tracking of approvals for new therapeutics in response to bioterrorism threats are accelerating market growth. The demand for stockpiling of anthrax therapeutics by governments and health organizations is also a significant driver, ensuring preparedness for potential outbreaks.

Furthermore, increasing collaborations between public and private sectors are fostering the development of more effective and accessible anthrax treatments. As these trends continue, the anthrax therapeutics market is poised for sustained growth, bolstered by continuous innovations and a robust pipeline of new products aimed at enhancing public health security.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Antibiotics segment, which is expected to reach US$420.5 Million by 2030 with a CAGR of a 7.1%. The Immunoglobulins segment is also set to grow at 6.7% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $110.7 Million in 2023, and China, forecasted to grow at an impressive 6.7% CAGR to reach $107.2 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Anthrax Therapeutics Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Anthrax Therapeutics Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Anthrax Therapeutics Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as AbVacc, Inc., Aphios Corporation, BlueWillow Biologics, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 86 Featured):

  • AbVacc, Inc.
  • Aphios Corporation
  • BlueWillow Biologics
  • Crestone
  • Elusys Therapeutics, Inc.
  • Emergent BioSolutions, Inc.
  • GC Biopharma corp.
  • Hawaii Biotech, Inc.
  • iNtRON Biotechnology
  • Lupin Ltd.
  • Paratek Pharmaceuticals
  • Pfizer Inc.
  • Porton Biopharma Limited
  • Soligenix
  • VLP Biotech

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Anthrax Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Heightened Awareness of Bioterrorism Threats Spurs Growth in Anthrax Therapeutics Market
  • Increased Government Funding for Biodefense Initiatives Expands Market Opportunity
  • Advancements in Medical Technology Propel Innovation in Anthrax Treatments
  • Demand for Stockpiling by Governments and Health Organizations Generates Steady Market Demand
  • Innovations in Antitoxins and Monoclonal Antibodies Propel Market Growth
  • Development of Next-Generation Vaccines Expands Addressable Market Opportunity
  • Use of Nanotechnology in Drug Delivery Enhances Efficacy and Reduces Side Effects
  • Economic and Geopolitical Factors Drive Investment in Biodefense Preparedness
  • Evolution of Pathogen Detection Technologies Supports Early Intervention and Treatment
  • Increased Focus on Long-Term Immunity Solutions Drives Vaccine Innovation
  • Advances in Genomic Research Generate Opportunities for Personalized Therapies
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Anthrax Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Anthrax Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Anthrax Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Anthrax Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Immunoglobulins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Immunoglobulins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Immunoglobulins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Hospitals Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Hospitals Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Anthrax Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 23: USA Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 24: USA Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 25: USA 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 26: USA Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 28: USA 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
CANADA
  • TABLE 29: Canada Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 30: Canada Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 31: Canada 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 34: Canada 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
JAPAN
  • Anthrax Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 35: Japan Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Japan Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 37: Japan 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Japan Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 40: Japan 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
CHINA
  • Anthrax Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 41: China Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 42: China Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 43: China 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 44: China Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 45: China Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 46: China 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
EUROPE
  • Anthrax Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 47: Europe Recent Past, Current & Future Analysis for Anthrax Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 48: Europe Historic Review for Anthrax Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 49: Europe 16-Year Perspective for Anthrax Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 52: Europe 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 55: Europe 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
FRANCE
  • Anthrax Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 56: France Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 57: France Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 58: France 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 59: France Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 60: France Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 61: France 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
GERMANY
  • Anthrax Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 62: Germany Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Germany Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 64: Germany 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 65: Germany Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Germany Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 67: Germany 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
ITALY
  • TABLE 68: Italy Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Italy Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 70: Italy 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 71: Italy Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Italy Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 73: Italy 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Anthrax Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 74: UK Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 75: UK Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 76: UK 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 77: UK Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 78: UK Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 79: UK 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
REST OF EUROPE
  • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Rest of Europe Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 82: Rest of Europe 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Rest of Europe Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 85: Rest of Europe 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Anthrax Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Asia-Pacific Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 88: Asia-Pacific 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Asia-Pacific Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 91: Asia-Pacific 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
REST OF WORLD
  • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Rest of World Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 94: Rest of World 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Rest of World Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 97: Rest of World 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbVacc, Inc.
  • Aphios Corporation
  • BlueWillow Biologics
  • Crestone
  • Elusys Therapeutics, Inc.
  • Emergent BioSolutions, Inc.
  • GC Biopharma corp.
  • Hawaii Biotech, Inc.
  • iNtRON Biotechnology
  • Lupin Ltd.
  • Paratek Pharmaceuticals
  • Pfizer Inc.
  • Porton Biopharma Limited
  • Soligenix
  • VLP Biotech

Table Information